News Merck & Co., Inc.

Equities

MRK

US58933Y1055

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 13:41:42 2026-03-13 EDT			5-day change	1st Jan Change
116.77 ^USD	+0.74%		+0.77%	+10.85%

03-12	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03-10	Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says	MT

All News

03-12	Wells Fargo Adjusts Price Target on Merck & Co. to $150 From $135, Maintains Overweight Rating	MT
03-10	Merck's Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says	MT
03-10	BioNTech founders plan exit to set up new venture, shares slump	RE
03-09	Global drugmakers rush to boost US presence as tariff threat looms	RE
03-06	Top pharma companies racing to launch a weight-loss pill	RE
03-04	Health Rounds: Laser treatment before immunotherapy helps brain cancer patients live longer	RE
03-03	Merck & Co., Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 01:50 PM
03-03	Tempus AI, Merck Collaborate on AI-Driven Precision Medicine	MT
03-03	Immunotherapy Delivers Across Tumor Types as Oncology Market Eyes $750 Billion	PR
03-03	Wolfe Adjusts Price Target on Merck to $142 From $135, Maintains Outperform Rating	MT
03-02	Merck - KEYTRUDA Plus Paclitaxel with or Without Bevacizumab Significantly Improved Key Secondary Endpoint of Overall Survival versus Paclitaxel with or without Bevacizumab in Patients	AQ
03-02	Merck - WELIREG plus LENVIMA Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients with Advanced Renal Cell Carcinoma	AQ
03-02	Merck - KEYTRUDA plus Padcev Reduced Risk of Event-Free Survival Events by 47% and Risk of Death by 35% for Cisplatin-Eligible Patients with Muscle-Invasive Bladder Cancer When Given Before and After Surgery	AQ
03-02	Merck - KEYTRUDA plus WELIREG Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients with Earlier-Stage Renal Cell Carcinoma	AQ
03-02	Leerink Partners Adjusts Price Target on Merck & Co to $129 From $128, Maintains Outperform Rating	MT
03-02	United Therapeutics' drug slows progression of rare lung condition in late-stage study	RE
03-02	Merck's Potential Renal Cancer Combos Show Significant Improvement in Meeting Primary Endpoints	MT
02-28	Merck & Co Inc says FDA sets PDUFA date of June 19, 2026 for Welireg and Keytruda	RE
02-28	KEYTRUDA® (pembrolizumab) Plus WELIREG® (belzutifan) Given as Adjuvant Therapy Reduced the Risk of Disease Recurrence or Death by 28% Compared to KEYTRUDA Monotherapy in Certain Patients With Earlier-Stage Renal Cell Carcinoma (RCC)	BU
02-28	Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda	CI
02-28	Merck says Welireg plus Lenvima reduces risk of disease progression by 30%	RE
02-28	WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)	BU
02-28	Merck Announces the Presentation of Results from the Pivotal Phase 3 Litespark-022 Trial Evaluating Keytruda	CI
02-27	Sector Update: Health Care Stocks Advance Late Afternoon	MT
02-27	Merck to lay off 154 employees	RE